Axogen (AXGN) EBITDA (2010 - 2026)

Axogen has reported EBITDA for 17 years, with the latest figure at -$2.2 million in Q2 2026.

• On a quarterly basis, EBITDA fell 228.95% year-over-year to -$2.2 million in Q2 2026; TTM through Jun 2026 was -$12.8 million, a 850.47% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, down 138.79% from the prior year.
• EBITDA was -$2.2 million for Q2 2026 at Axogen, up from -$2.8 million in the prior quarter.
• The five-year high for EBITDA was $2.0 million in Q4 2024, with the low at -$11.3 million in Q1 2022.
• Average EBITDA over 5 years is -$3.7 million, with a median of -$3.6 million recorded in 2023.
• The largest YoY upside for EBITDA was 705.06% in 2025 against a maximum downside of 584.48% in 2025.
• Over 5 years, EBITDA stood at -$5.6 million in 2022, then surged by 43.05% to -$3.2 million in 2023, then soared by 163.15% to $2.0 million in 2024, then tumbled by 584.48% to -$9.8 million in 2025, then soared by 77.94% to -$2.2 million in 2026.
• The last three EBITDA figures came in at -$2.2 million (Q2 2026), -$2.8 million (Q1 2026), and -$9.8 million (Q4 2025), per Business Quant data.